Author

Jaehyoung Jeon

Institution: ABL Bio (South Korea)

Observed institution: ABL Bio (South Korea)

ORCID: 0000-0002-3406-8260

Observed ORCID: 0000-0002-3406-8260

OpenAlex ID: A5028472454

LAG-3xPD-L1 bispecific antibody potentiates antitumor responses of T cells through dendritic cell activation

2022 · Eunsil Sung, Minkyung Ko, et al. · Molecular Therapy · 84

Novel anti-4-1BB×PD-L1 bispecific antibody augments anti-tumor immunity through tumor-directed T-cell activation and checkpoint blockade

2021 · Seongju Jeong, Eunyoung Park, et al. · Journal for ImmunoTherapy of Cancer · 63

Anti–4-1BB×PDL1 Bispecific Antibody Reinvigorates Tumor-Specific Exhausted CD8+ T Cells and Enhances the Efficacy of Anti-PD1 Blockade

2024 · Seung Hyuck Jeon, Gihoon You, et al. · Clinical Cancer Research · 17

Data from Anti–4-1BB×PDL1 Bispecific Antibody Reinvigorates Tumor-Specific Exhausted CD8+ T Cells and Enhances the Efficacy of Anti-PD1 Blockade

2024 · Seung Hyuck Jeon, Gihoon You, et al. · 1

Supplementary Figures S1-7 from Anti–4-1BB×PDL1 Bispecific Antibody Reinvigorates Tumor-Specific Exhausted CD8+ T Cells and Enhances the Efficacy of Anti-PD1 Blockade

2024 · Seung Hyuck Jeon, Gihoon You, et al.

Supplementary Tables 1-3 from Anti–4-1BB×PDL1 Bispecific Antibody Reinvigorates Tumor-Specific Exhausted CD8+ T Cells and Enhances the Efficacy of Anti-PD1 Blockade

2024 · Seung Hyuck Jeon, Gihoon You, et al.

Data from Anti–4-1BB×PDL1 Bispecific Antibody Reinvigorates Tumor-Specific Exhausted CD8+ T Cells and Enhances the Efficacy of Anti-PD1 Blockade

2024 · Seung Hyuck Jeon, Gihoon You, et al.

Supplementary Tables 4-7 from Anti–4-1BB×PDL1 Bispecific Antibody Reinvigorates Tumor-Specific Exhausted CD8+ T Cells and Enhances the Efficacy of Anti-PD1 Blockade

2024 · Seung Hyuck Jeon, Gihoon You, et al.

Supplementary Tables 4-7 from Anti–4-1BB×PDL1 Bispecific Antibody Reinvigorates Tumor-Specific Exhausted CD8+ T Cells and Enhances the Efficacy of Anti-PD1 Blockade

2024 · Seung Hyuck Jeon, Gihoon You, et al.

845 ABL503 (TJ-L14B), PD-L1×4–1BB bispecific antibody, reinvigorates exhausted tumor-infiltrating CD8+T cells and synergizes with PD-1 blockade

2023 · Gihoon You, Seung Hyuck Jeon, et al. · Journal for ImmunoTherapy of Cancer

892 ABL503 (TJ-L14B), PD-L1x4–1BB bispecific antibody induces superior anti-tumor activity by PD-L1-dependent 4–1BB activation with the increase of 4–1BB+CD8+ T cells in tumor microenvironment

2021 · Uijung Jung, Jaehyoung Jeon, et al. · Journal for ImmunoTherapy of Cancer

Works count: 11

Citation count: 165

H-index: 3

I10-index: 3